Arcturus differentiates through its LUNAR delivery platform designed for tissue-specific mRNA targeting, enabling treatment of genetic disorders where conventional therapies are limited. The company is advancing multiple pipeline candidates toward pivotal studies, with regulatory alignment meetings planned for early 2026 and commercial partnerships including CSL for vaccine commercialization.
Cyborg Score Rationale
The company shows promising clinical data with mucus burden reductions in cystic fibrosis trials and positive OTC deficiency interim results, supporting its technology platform. However, significant revenue headwinds, negative operating margins, and early-stage pipeline development present substantial execution risk and cash burn concerns.
Top Insights
ARCT-032 CF Phase 2 interim data (Oct 2025) showed mucus volume reductions in 4 of 6 Class I patients with robust safety; expanded 12-week study planned for H1 2026
ARCT-810 OTC deficiency Phase 2 demonstrated statistically significant improvements in glutamine levels with positive safety profile; regulatory alignment for pivotal trials expected H1 2026
Revenue declined 63.54% YoY (9M 2025) largely due to reduced CSL collaboration activity; operating expenses decreased 36% in Q3 2025 reflecting cost management initiatives
Cash position of $237.3M extends runway into 2028 after Q4 2025 cost reductions; analyst consensus rating is Buy with $35.75 price target as of Feb 2026
Named Competitors
Moderna — Large-cap mRNA therapeutics and vaccine platform company
Intellia Therapeutics — Gene editing and mRNA-based rare disease therapies
Sarepta Therapeutics — Gene therapy and RNA medicine for rare diseases
Sangamo Therapeutics — Gene editing platform for genetic disorders
Recent Developments
(March 2026) Arcturus scheduled to report 4Q and FY 2025 results with corporate update on March 3, 2026
(January 2026) CEO Joseph Payne presented at J.P. Morgan Healthcare Conference
(November 2025) Meiji Seika Pharma launched KOSTAIVE JN.1 variant vaccine in Japan following PMDA approval in August 2025
(October 2025) ARCT-032 CF Phase 2 interim results published showing mucus plug reductions and early FEV1 improvements
Open the full interactive Arcturus Therapeutics Holdings Inc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.